LOGIN  |  REGISTER
Astria Therapeutics
Assertio

GE HealthCare and Mass General Brigham Evolve Their AI Collaboration with Medical Imaging Foundation Models

March 12, 2024 | Last Trade: US$77.09 2.16 -2.73

ORLANDO, Fla. / Mar 12, 2024 / Business Wire / Based on its long-term artificial intelligence (AI) partnership, GE HealthCare and Mass General Brigham plan to integrate medical imaging foundation models into their AI research work, with a strong focus on responsible AI practices. Both organizations have been working closely on AI solutions since announcing their 10-year commitment in 2017 to explore the use of AI across a broad range of diagnostic and treatment paradigms through sustainable AI development.

“The relationship between Mass General Brigham’s commercial AI business (Mass General Brigham AI) and GE HealthCare has helped accelerate the introduction of AI into a range of product offerings and digital health solutions. With foundation models, we are witnessing the next wave of AI innovation, and it is already reshaping how we build, integrate and use AI,” said Dr. Keith Dreyer, Chief Data Science Officer, Mass General Brigham. “I think we are all optimistic that foundation models may actually complement and enhance the work we have been doing with convolutional neural networks over the past few years. Hopefully, this work will help make healthcare delivery more efficient for our practitioners, more accessible for our patients and more equitable for our diverse communities.”

The traditional approach to integrating AI into healthcare systems requires the retraining of models to accommodate the unique requirements of different patient populations and hospital settings. This can lead to increased costs and complexity, and in addition, hinder the broad adoption of AI technologies in the healthcare industry. Foundation models have the potential to transform healthcare by improving workflow efficiency and imaging diagnosis, since they have demonstrated strong capabilities in solving a diverse set of tasks. Foundation models have emerged as a reliable and adaptable foundation for developing AI applications tailored to the healthcare sector.

“GE HealthCare and Mass General Brigham have a long-standing AI collaboration that has produced AI-powered tools which help increase operational effectiveness and productivity. Now, with adding foundation models to our research work, we will be able to take the next step of digital and AI transformation to develop technology innovations that provide better patient care and outcomes,” said Parminder Bhatia, Chief AI Officer, GE HealthCare. "Incorporating responsible AI practices into this phase, we are committed to ensuring these innovations adhere to guidelines, prioritize patient safety and privacy, and promote fairness and transparency across all applications."

To learn more about GE HealthCare’s digital and AI technologies, visit here.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on Facebook, LinkedIn, Twitter, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB